SCHEMBL305215

SCHEMBL305215

[CH2]S([NH])(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2790344 0.72
SCHEMBL2339270 0.72
SCHEMBL19838028 0.67
SCHEMBL6135306 0.67
SCHEMBL8802624 0.67
SCHEMBL1756627 0.64
SCHEMBL184294 0.62
SCHEMBL148135 0.62
SCHEMBL108578 0.62
SCHEMBL1727714 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060111274-A1 Methods and compositions for enhancing transport across biological membranes THE BOARD OF TRUSTEES OF THE LELAND STANFORD (US) 2006-05-25 US claimed
EP-0975370-B9 COMPOSITION AND METHOD FOR ENHANCING TRANSPORT ACROSS BIOLOGICAL MEMBRANES UNIV LELAND STANFORD JUNIOR (US) 2004-11-03 EP claimed
EP-0975370-B1 COMPOSITION AND METHOD FOR ENHANCING TRANSPORT ACROSS BIOLOGICAL MEMBRANES UNIV LELAND STANFORD JUNIOR (US) 2003-10-15 EP claimed
US-20030162719-A1 Method and composition for enhancing transport across biological membranes NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-08-28 US claimed
EP-0483667-B1 Cyclic imino derivatives, process for their preparation and drugs containing them THOMAE GMBH DR K (DE) 1998-02-04 EP claimed
US-20240216486-A1 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES REVANCE THERAPEUTICS, INC. 2024-07-04 US disclosed
US-11911449-B2 Albumin-free botulinum toxin formulations REVANCE THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
US-20240058628-A1 INJECTABLE BOTULINUM TOXIN FORMULATIONS JPMORGAN CHASE BANK, N.A. 2024-02-22 US disclosed
CN-117279654-A Method for treating cervical dystonia 雷文斯治疗公司 2023-12-22 CN disclosed
US-20230210963-A1 INJECTABLE BOTULINUM TOXIN METHOS FOR TREATING HEADACHES REVANCE THERAPEUTICS, INC. 2023-07-06 US disclosed
EP-4121169-A2 INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES ReVance Therapeutics, Inc. (US) 2023-01-25 EP disclosed
US-20220347275-A1 Methods and Compositions for Treating Skin Conditions Associated With Vascular Hyper-reactivity REVANCE THERAPEUTICS, INC. (US) 2022-11-03 US disclosed
US-6306406-B1 FOR CONTOLLED RELEASE OF CALCITONIN UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2001-10-23 US disclosed
WO-2001062297-A1 COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS BIOLOGICAL MEMBRANES AND TISSUES CELLGATE, INC. (US) 2001-08-30 WO disclosed
WO-2001013957-A2 ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES USING OLIGO ARGININE MOIETIES CELLGATE, INC. (US) 2001-03-01 WO disclosed
EP-0975370-A2 COMPOSITION AND METHOD FOR ENHANCING TRANSPORT ACROSS BIOLOGICAL MEMBRANES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2000-02-02 EP disclosed
EP-0467389-B1 Drug delivery system comprising interaction between calcitonin and a hydrophobic biodegradable polymer UNIV KENTUCKY RES FOUND (US) 1999-10-06 EP disclosed
WO-1998052614-A2 COMPOSITION AND METHOD FOR ENHANCING TRANSPORT ACROSS BIOLOGICAL MEMBRANES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1998-11-26 WO disclosed
EP-0467389-A2 Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1992-01-22 EP disclosed
US-4897444-A Immobilized fluorogenic substrates for enzymes; and processes for their preparation THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) 1990-01-30 US disclosed